9. Новое в классификации эпителиальных опухолей поджелудочной железы (воз, 2019, 5-е издание)

Авторы

  • В.Б. Гринберг National Scientific Center of Surgery», Almaty, Kazakhstan, Сызганова», г. Алматы, Казахстан
  • Е.А. Енин National Scientific Center of Surgery», Almaty, Kazakhstan, Сызганова», г. Алматы, Казахстан

Загрузки

Аннотация

Большая часть классификации эпителиальных опухолей поджелудочной железы в 5-м издании остаётся неизменной по сравнению с предыдущим изданием. В новой классификации предраковые поражения, классифицируются по двум уровням дисплазии. Внутрипротоковые онкоцитарные папиллярные опухоли и внутрипротоковые онкоцитарные папиллярные опухоли, ассоциированная с инвазивной карциномой отделены от других подтипов. Некоторые изменения произошли в классификации TNM.

Ключевые слова

классификация, эпителиальные опухоли

Библиографические ссылки

  1. Lowe GD, Rumley A, Mackie IJ. Plasma fibrinogen. Ann ClinBiochem 2004; 41:430-40
  2. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. AnesthAnalg 1995;81:360-5
  3. Stainsby D, MacLennan S, Thomas D, et al. Guidelines on the management of massive blood loss. Br J Haematol 2006;135:634-41
  4. Velik-Salchner C, Haas T, Innerhofer P, et al. The effect of fibrinogen concentrate on throm­bo­ cytopenia. J ThrombHaemost 2007; 5:1019-25
  5. Schöchl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010;14:R55
  6. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008;64:S79-85
  7. Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus 2012;10: 23-7
  8. Kreuz W, Meili E, Peter-Salonen K, et al. Phar­ ma­cokinetic properties of a pasteurised fibrinogen concentrate. TransfusApherSci 2005; 32:239-46
  9. Martinez J, Holburn RR, Shapiro SS, et al. Fibrinogen Philadelphia. A hereditary hypodys­fib­ rinogenemia characterized by fibrino­gen hyper­ catabolism. J Clin Invest 1974; 53:600-11
  10. Martini WZ, Chinkes DL, Pusateri AE, et al. Acute changes in fibrinogen metabolism and coagulation after hemorrhage in pigs. Am J PhysiolEndocrinolMetab 2005;289: E930-4
  11. McLoughlin TM, Fontana JL, Alving B, et al. Profound normovolemichemodilution: hemostatic effects in patients and in a porcine model. AnesthAnalg 1996;83: 459-65
  12. De Lorenzo C, Calatzis A, Welsch U, et al. Fibrinogen concentrate reverses dilutional coa­gulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. AnesthAnalg 2006; 102:1194-200
  13. Fenger-Eriksen C, Anker-Moller E, Heslop J, et al. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: im­ pro­vements of the induced coagulopathy with fib­ rinogen concentrate. Br J Anaesth 2005;94:324-9
  14. Fries D, Krismer A, Klingler A, et al. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 2005;95:172-7
  15. Martini J, Maisch S, Pilshofer L, et al. Fibrinogen concentrate in dilutional coagulopathy: a dose study in pigs. Transfusion 2013. doi:10.1111/trf.12241
  16. Fenger-Eriksen C, Ingerslev J, Sorensen B. Fibrinogen concentrate – a potential universal hemostatic agent. Expert OpinBiolTher 2009; 9:1325-33
  17. Parasnis H, Raje B, Hinduja IN. Relevance of plasma fibrinogen estimation in obstetric complications. J Postgrad Med 1992;38:183-5
  18. European Medicines Agency.Guideline on core SPC for human plasma fibrinogen products (EMEA/ CHMP/ BPWP/122007/2005). 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2009/09/WC500003296. pdf
  19. Dempfle CE, Kalsch T, Elmas E, et al. Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots. Blood Coagul Fibrinolysis 2008;19:765-70
  20. Spahn DR, Cerny V, Coats TJ, et al.; Task Force for Advanced Bleeding Care in Trauma. Management of bleeding following major trauma: a European guideline. Crit Care 2007;11:R17
  21. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an up­ dated report. Anesthesiology 2006;105:198-208
  22. Bolliger D, Szlam F, Molinaro RJ, et al. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009;102:793-9
  23. Karkouti K, Callum J, Crowther MA, et al. The relationship between fibrinogen levels after car­ dio­pulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study. AnesthAnalg 2013;117:14-22
  24. Bolliger D, Gonsahn M, Levy JH, et al. Is pre­ope­ra­ tive fibrinogen predictive for pos­to­pe­rative bleeding after coronary artery bypass graf­ting surgery? Transfusion 2009; 49:2006-7; author reply 2007-8
  25. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17:R76
  26. Snyder CW, Weinberg JA, McGwin G Jr, et al. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma 2009; 66:358-62
  27. Goodnough LT, Spain DA, Maggio P. Logistics of transfusion support for patients with massive he­ mor­rhage. CurrOpinAnaesthesiol 2013; 26:208-14
  28. Goodnough LT, Shander A. How I treat warf­a­rin­ associated coagulopathy in patients with intra­ce­ rebral hemorrhage. Blood 2011;117:6091-9
  29. Groner A. Reply. Pereira A. Cryoprecipitate ver­ sus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusiontransmitted infection. Hae­ ma­tologica 2007;92:846-9. Haematologica 2008; 93:e24-6; author reply e27
  30. Bell SF, Rayment R, Collins PW, et al. The use of fibrinogen concentrate to correct hypo­fib­rino­ genaemia rapidly during obstetric haemorrhage. Int J ObstetAnesth 2010; 19:218-23
  31. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008;101:769-73

Опубликован

2022-06-22

Выпуск

№ 2 (2022)

Раздел

Статьи